Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rxbWlEPTB;MD6wNFAzQDdizszN NIPYS3NUSU6JRWK=
LC-2-ad NH3JXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\p[mlEPTB;MD6wNFA{OTdizszN NHfDPVhUSU6JRWK=
RL95-2 NFHVU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHuTWM2OD1yLkCwNFY3QCEQvF2= Mmr6V2FPT0WU
MZ1-PC NHrSbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;kcmlEPTB;MD6wNFA4OjlizszN MYDTRW5ITVJ?
TE-8 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnB[nNKSzVyPUCuNFAyOTdizszN MX7TRW5ITVJ?
SW954 NUDldmNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojoTWM2OD1yLkCwNVE6KM7:TR?= MWDTRW5ITVJ?
TE-11 NITHc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDZOHBKSzVyPUCuNFAyOjNizszN NV7TdYs1W0GQR1XS
PSN1 Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTFTWM2OD1yLkCwNVMh|ryP NIPLVFFUSU6JRWK=
MOLT-4 MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFziOVNKSzVyPUCuNFAyPDlizszN NUjOfVl4W0GQR1XS
697 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmOwTWM2OD1yLkCwNVUh|ryP Mn;1V2FPT0WU
ETK-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPST29KSzVyPUCuNFAyPTJizszN MnzBV2FPT0WU
TE-10 M333O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMECxOVQh|ryP MlfMV2FPT0WU
HUTU-80 NIDyRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjsfWVvUUN3ME2wMlAxOTZ6IN88US=> NGHhcZhUSU6JRWK=
NTERA-S-cl-D1 NX;3S|M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3FTZV3UUN3ME2wMlAxOjB7IN88US=> NV3B[XgzW0GQR1XS
MFH-ino NWC1PGRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHDfVFKSzVyPUCuNFAzPjhizszN NXjxO5FtW0GQR1XS
IA-LM Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLwTWM2OD1yLkCwNlgh|ryP NYHkOHo6W0GQR1XS
MC116 MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrrTWM2OD1yLkCwNlg6KM7:TR?= NXjVVGFsW0GQR1XS
RKO MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfydWNuUUN3ME2wMlAxOjl6IN88US=> NYLqfYljW0GQR1XS
MRK-nu-1 NInQXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm1RoFvUUN3ME2wMlAxOjl7IN88US=> NHv5eWpUSU6JRWK=
VA-ES-BJ NWGxR5p5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHy0[YxKSzVyPUCuNFA{KM7:TR?= NF3kPVdUSU6JRWK=
KALS-1 M1joNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DENmlEPTB;MD6wNFMxQCEQvF2= NYnl[nRHW0GQR1XS
BB30-HNC M3\RXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTnflRUUUN3ME2wMlAxOzF2IN88US=> MnHlV2FPT0WU
ACN NUTUdFl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TwRWlEPTB;MD6wNFMyPiEQvF2= M1jaTXNCVkeHUh?=
TE-9 NFHuO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfQTWM2OD1yLkCwN|I3KM7:TR?= M4TJfHNCVkeHUh?=
SIG-M5 M4jt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzZUlhKSzVyPUCuNFA{OjdizszN MWrTRW5ITVJ?
no-10 NXP3cpNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe2UIdKSzVyPUCuNFA{PjJizszN MkTJV2FPT0WU
EW-1 NWO2OIRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMECzO|Eh|ryP MYHTRW5ITVJ?
SK-LMS-1 NVy2R4hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fy[WlEPTB;MD6wNFQxOSEQvF2= MnLlV2FPT0WU
GT3TKB NFfmZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMEC0N|Qh|ryP NG\sXmdUSU6JRWK=
ES4 NXLhflV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;kPFVUUUN3ME2wMlAxPDR7IN88US=> MoDmV2FPT0WU
IMR-5 NIniTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHmVJhKSzVyPUCuNFA1PSEQvF2= NFjVcZVUSU6JRWK=
NCI-H1648 M1\lTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fabmlEPTB;MD6wNFQ3QSEQvF2= M2DDOnNCVkeHUh?=
MV-4-11 NIP2WIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HFS2lEPTB;MD6wNFQ4PSEQvF2= Mn[5V2FPT0WU
SK-UT-1 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33ibmlEPTB;MD6wNFQ5KM7:TR?= M1rQS3NCVkeHUh?=
NB13 NEXZUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nRdWlEPTB;MD6wNFQ6OSEQvF2= MkLDV2FPT0WU
DJM-1 M3nw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEC1N{DPxE1? NEmxN29USU6JRWK=
ES8 NHTXV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4riO2lEPTB;MD6wNFU{QCEQvF2= MkPJV2FPT0WU
TE-6 MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XNfGlEPTB;MD6wNFU4KM7:TR?= NFiwNndUSU6JRWK=
KS-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3HeYhJUUN3ME2wMlAxPTh{IN88US=> Ml\hV2FPT0WU
TE-1 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f0N2lEPTB;MD6wNFYxPiEQvF2= M1XVVXNCVkeHUh?=
ATN-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn1S3JKSzVyPUCuNFA3ODlizszN NX\YfZBwW0GQR1XS
A4-Fuk NYfSXoJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD1UHNvUUN3ME2wMlAxPjFzIN88US=> MYHTRW5ITVJ?
ALL-PO MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHzdmlKSzVyPUCuNFA3OyEQvF2= Mlv0V2FPT0WU
BE-13 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPnTWM2OD1yLkCwOlM3KM7:TR?= MojYV2FPT0WU
KM12 M3X4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\WR|JKSzVyPUCuNFA3OzdizszN NUm2bXhYW0GQR1XS
NOS-1 NWrUXFcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jNUGlEPTB;MD6wNFY2KM7:TR?= MUHTRW5ITVJ?
SW962 NEDiUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPIZ5VKSzVyPUCuNFA3PjJizszN MlO1V2FPT0WU
OCUB-M M2P0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEC2OlIh|ryP NWPiXY9YW0GQR1XS
NCI-H510A Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr6eoJRUUN3ME2wMlAxPjZ3IN88US=> M4TNcXNCVkeHUh?=
EW-16 MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD6OGNqUUN3ME2wMlAxPjl2IN88US=> MU\TRW5ITVJ?
KGN NILOV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX3SHNKSzVyPUCuNFA4OTJizszN NHnj[mlUSU6JRWK=
LS-411N MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDsR|dYUUN3ME2wMlAxPzF5IN88US=> MkPjV2FPT0WU
Becker NWDp[mRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DF[mlEPTB;MD6wNFczKM7:TR?= NHjTV3ZUSU6JRWK=
HC-1 NInBfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfab4JKSzVyPUCuNFA4OjFizszN Mnv0V2FPT0WU
CESS M{\1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEC3N|ch|ryP NYOw[os1W0GQR1XS
KURAMOCHI MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXXNFVRUUN3ME2wMlAxPzR6IN88US=> M{Tve3NCVkeHUh?=
TGBC24TKB MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMEC3OVIh|ryP NFLjSW1USU6JRWK=
SW982 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3HdFg2UUN3ME2wMlAxPzZ4IN88US=> NGrJWXZUSU6JRWK=
HCE-4 NUXsUmxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEC3Olch|ryP MVXTRW5ITVJ?
LOUCY NF\4b3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfCTWM2OD1yLkCwO|c2KM7:TR?= NXLTOm46W0GQR1XS
8-MG-BA M4nPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTEUmZKSzVyPUCuNFA4QTZizszN NVr3R3JlW0GQR1XS
HT-144 M2LPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDvTWM2OD1yLkCwPEDPxE1? M{LicXNCVkeHUh?=
LXF-289 M13LSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfmcZZ{UUN3ME2wMlAxQDF6IN88US=> MVrTRW5ITVJ?
RS4-11 NX3X[WxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMEC4N|Yh|ryP NXfNXZVbW0GQR1XS
DEL NEHuUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MniyTWM2OD1yLkCwPFQ2KM7:TR?= MoH0V2FPT0WU
OCI-AML2 M4jycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMEC4OVIh|ryP MkThV2FPT0WU
CCRF-CEM NGHPTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEC4O|Eh|ryP MlyzV2FPT0WU
A388 NYn6e3BOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMEC4O|Qh|ryP NU\pTGNxW0GQR1XS
KNS-42 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TnPGlEPTB;MD6wNFg6OSEQvF2= NYTae4xMW0GQR1XS
OVCAR-4 Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzlNVJKSzVyPUCuNFA6ODRizszN MXHTRW5ITVJ?
NCI-H1355 NHjnUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPhcIU{UUN3ME2wMlAxQTF2IN88US=> NXTIU|Q1W0GQR1XS
BL-70 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXRTWM2OD1yLkCwPVMh|ryP NGrqepJUSU6JRWK=
BL-41 M3nk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGzd2tKSzVyPUCuNFA6OzRizszN NWf3Z|l1W0GQR1XS
A101D MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PYSWlEPTB;MD6wNFk3KM7:TR?= NWnvOFZmW0GQR1XS
HL-60 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnVTVFEUUN3ME2wMlAxQTZ4IN88US=> NXfRdodIW0GQR1XS
COR-L279 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK3TWM2OD1yLkCwPVk6KM7:TR?= NGDuN|VUSU6JRWK=
NCI-SNU-16 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjEZY9KSzVyPUCuNFExODhizszN NIrPWpFUSU6JRWK=
Calu-6 NEnPW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LFSWlEPTB;MD6wNVAyOiEQvF2= MnHxV2FPT0WU
SR Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMEGwNlYh|ryP MV7TRW5ITVJ?
QIMR-WIL NGfRe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMEGwN|Mh|ryP MV\TRW5ITVJ?
LB647-SCLC NUnHc3I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTUUlRkUUN3ME2wMlAyODVzIN88US=> NGLWOZVUSU6JRWK=
RPMI-8226 NUXIXGMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfnTWM2OD1yLkCxNVAzKM7:TR?= MYHTRW5ITVJ?
SK-PN-DW M3zHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z3RWlEPTB;MD6wNVEyOiEQvF2= NWDxXWNIW0GQR1XS
SF268 M{j5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vmNGlEPTB;MD6wNVE2OSEQvF2= NEjCcZRUSU6JRWK=
HD-MY-Z NVrad21WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMEGxOlMh|ryP NX\GeXhJW0GQR1XS
DOHH-2 NX\sVWZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMEGyNFMh|ryP M2\TcXNCVkeHUh?=
SCC-3 MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7HOGtyUUN3ME2wMlAyOjB2IN88US=> M{\hPHNCVkeHUh?=
ST486 MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEGyNFQh|ryP M{HwW3NCVkeHUh?=
NALM-6 MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHxOJNKSzVyPUCuNFEzOTRizszN NWPnV2lSW0GQR1XS
NCI-H1436 Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7Vc3dKSzVyPUCuNFEzOzFizszN M1yzb3NCVkeHUh?=
KE-37 NHX2d49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEGyN|Qh|ryP M3\rSXNCVkeHUh?=
RPMI-8402 NHTlT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P5XGlEPTB;MD6wNVI2PiEQvF2= MlLYV2FPT0WU
RXF393 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\hN2lEPTB;MD6wNVI2PyEQvF2= M{jXXnNCVkeHUh?=
KARPAS-45 NUjJ[pM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHvTWM2OD1yLkCxNlch|ryP M3P4VHNCVkeHUh?=
HOP-62 MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXBO3dKSzVyPUCuNFEzPzZizszN NFLGN5RUSU6JRWK=
ES1 NES3emNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPCN|V6UUN3ME2wMlAyOjh6IN88US=> MX\TRW5ITVJ?
L-363 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\lb2lEPTB;MD6wNVM2OSEQvF2= M4X6WnNCVkeHUh?=
GI-1 NGe3PJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMEGzO|Mh|ryP MWXTRW5ITVJ?
CTV-1 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPMdItOUUN3ME2wMlAyPDd6IN88US=> NEDGcmpUSU6JRWK=
TE-5 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrrR2YyUUN3ME2wMlAyPDl4IN88US=> M160fnNCVkeHUh?=
SNU-C2B NWeyOGkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMEG0PVYh|ryP NVfwUlFmW0GQR1XS
K-562 M3;o[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHzTWM2OD1yLkCxOVE3KM7:TR?= NEfwbZJUSU6JRWK=
SNB75 M4mzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PwWmlEPTB;MD6wNVU1KM7:TR?= MnPmV2FPT0WU
MOLT-13 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEG2N|ch|ryP NGi0UIxUSU6JRWK=
LS-123 NEHnXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq0VlBKSzVyPUCuNFE3PjRizszN NWnZOYtHW0GQR1XS
NCI-SNU-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Hm[GlEPTB;MD6wNVcxOSEQvF2= MUnTRW5ITVJ?
Daudi M3e4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPnbYtKSzVyPUCuNFE4ODhizszN M4r2TXNCVkeHUh?=
A253 MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK3UGRKSzVyPUCuNFE4OzhizszN MV7TRW5ITVJ?
TGBC1TKB NHy0c2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PG[mlEPTB;MD6wNVc2OiEQvF2= M{DYV3NCVkeHUh?=
SJSA-1 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D2UmlEPTB;MD6wNVc3PyEQvF2= NGLZTZRUSU6JRWK=
NCCIT M1;VO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS2W3VKSzVyPUCuNFE4PjlizszN NXHCOHZiW0GQR1XS
NCI-H69 NV:4c2wzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MontTWM2OD1yLkCxO|c5KM7:TR?= Mm\FV2FPT0WU
SH-4 M13Ec2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPGVnJKSzVyPUCuNFE5QTVizszN MnvOV2FPT0WU
HCC1187 Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrDTWM2OD1yLkCxPVI1KM7:TR?= MoPZV2FPT0WU
HCC1599 NUfQcFdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofLTWM2OD1yLkCyNFIh|ryP MnPBV2FPT0WU
ONS-76 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3CTWM2OD1yLkCyNFM3KM7:TR?= M2LlfXNCVkeHUh?=
KU812 NHfOeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELPV4pKSzVyPUCuNFIxOzlizszN M3LQcXNCVkeHUh?=
ML-2 M4HpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S3NWlEPTB;MD6wNlA1PyEQvF2= MojuV2FPT0WU
HCE-T MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;kTWM2OD1yLkCyNFkzKM7:TR?= M3H6c3NCVkeHUh?=
NCI-H446 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[zNIxKSzVyPUCuNFIyOTJizszN M2nUXnNCVkeHUh?=
RPMI-6666 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly5TWM2OD1yLkCyNVQ6KM7:TR?= M2DuNXNCVkeHUh?=
MOLT-16 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMEKxOVMh|ryP NYjYPJM4W0GQR1XS
JiyoyeP-2003 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M123bGlEPTB;MD6wNlE4PiEQvF2= Mny4V2FPT0WU
MHH-PREB-1 M3HBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMEKxPVEh|ryP M{DvRXNCVkeHUh?=
MC-CAR NULJWpdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXJb5RkUUN3ME2wMlAzOzJ4IN88US=> M2DHdnNCVkeHUh?=
BC-3 Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nI[GlEPTB;MD6wNlM1PCEQvF2= MkXQV2FPT0WU
KINGS-1 M13vVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMEKzOVUh|ryP Ml3XV2FPT0WU
PF-382 M1nRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfuVVlKSzVyPUCuNFI{PzhizszN M2[5dnNCVkeHUh?=
J-RT3-T3-5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DkTmlEPTB;MD6wNlM5OyEQvF2= NVL4Nm9QW0GQR1XS
SF539 NWfxXmxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[4U4RwUUN3ME2wMlAzPDBzIN88US=> MoXNV2FPT0WU
LB831-BLC NED1[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLafG9TUUN3ME2wMlAzPDh3IN88US=> MlLRV2FPT0WU
DMS-114 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rHNWlEPTB;MD6wNlUxOiEQvF2= MVTTRW5ITVJ?
LB1047-RCC MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzhbVBKSzVyPUCuNFI2OSEQvF2= NEXWW|hUSU6JRWK=
LB771-HNC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDXTWM2OD1yLkCyOVM1KM7:TR?= M17HcXNCVkeHUh?=
BB65-RCC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfFVIFKSzVyPUCuNFI2OzRizszN MkXjV2FPT0WU
BV-173 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMEK1OVQh|ryP MWHTRW5ITVJ?
ARH-77 NHHSUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXpV5VKSzVyPUCuNFI3ODFizszN M3TicHNCVkeHUh?=
IST-MEL1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfCTWM2OD1yLkCyOlI{KM7:TR?= NYLvZ4dOW0GQR1XS
NB1 NWHkZmRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULqNlRjUUN3ME2wMlAzPjh5IN88US=> M{nEcXNCVkeHUh?=
EoL-1-cell MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEK2PFgh|ryP MlPqV2FPT0WU
KY821 NXLCOWd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEK2PVch|ryP M4rSS3NCVkeHUh?=
CMK MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMEK3N|Qh|ryP MUjTRW5ITVJ?
NCI-H2126 NVTqZZlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Tke2lEPTB;MD6wNlc3QCEQvF2= NUDBRnQ6W0GQR1XS
NCI-H526 MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OzSWlEPTB;MD6wNlg6OSEQvF2= M320XnNCVkeHUh?=
COLO-684 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMEK5NFgh|ryP NHq5bWdUSU6JRWK=
NCI-H747 M4nHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTvR2NKSzVyPUCuNFI6OzNizszN NV\OOFR{W0GQR1XS
JAR MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXMS4s1UUN3ME2wMlAzQTR4IN88US=> NF\XW3NUSU6JRWK=
MEG-01 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMEK5O|gh|ryP NXrMfIc2W0GQR1XS
MONO-MAC-6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPmTWM2OD1yLkCzNFI{KM7:TR?= NWnFSnJoW0GQR1XS
IST-SL1 NVLvTJJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX6O3pKSzVyPUCuNFMxPDJizszN MWjTRW5ITVJ?
CPC-N NF;ZeIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMEOwO|kh|ryP NGPUU3lUSU6JRWK=
NCI-H1963 NGfkZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMEOxN|Eh|ryP MWTTRW5ITVJ?
K052 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn4b3pQUUN3ME2wMlA{OjR5IN88US=> M{HVUHNCVkeHUh?=
KM-H2 NX;wfmhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LnV2lEPTB;MD6wN|MxPyEQvF2= MVrTRW5ITVJ?
TE-12 M3nFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC4eIFDUUN3ME2wMlA{OzB7IN88US=> NYP0WVRrW0GQR1XS
TK10 NGjtbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr1TWM2OD1yLkCzN|U3KM7:TR?= MojQV2FPT0WU
NMC-G1 MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCz[XhOUUN3ME2wMlA{PDV{IN88US=> M3T4UXNCVkeHUh?=
no-11 NHzMbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vwUWlEPTB;MD6wN|Q4QCEQvF2= NXW4WpJuW0GQR1XS
NCI-H524 NX:4W5BQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEO1Nlkh|ryP MUfTRW5ITVJ?
MHH-CALL-2 NE\vdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;JeXFPUUN3ME2wMlA{PTZ{IN88US=> NEjp[|NUSU6JRWK=
GB-1 NWLtcnpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{juRmlEPTB;MD6wN|Yh|ryP Mo[3V2FPT0WU
OPM-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMEO2O|Mh|ryP NGT0[4ZUSU6JRWK=
RH-1 NFzXRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLWVYNKSzVyPUCuNFM5OTlizszN NVnhZXo4W0GQR1XS
NCI-H64 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXRTWM2OD1yLkCzPFU4KM7:TR?= MnLOV2FPT0WU
EVSA-T NIrETJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWiyeHdnUUN3ME2wMlA{QTJ|IN88US=> NVuxTFBJW0GQR1XS
KARPAS-299 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorvTWM2OD1yLkCzPVgh|ryP M4KwO3NCVkeHUh?=
MZ7-mel MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMESwOEDPxE1? MYHTRW5ITVJ?
LB373-MEL-D NYnqNZd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDBfVA6UUN3ME2wMlA1OTB3IN88US=> MWHTRW5ITVJ?
HEL NV\1eYVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n5eWlEPTB;MD6wOFE1KM7:TR?= MY\TRW5ITVJ?
SW872 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMESyNUDPxE1? NWj1ZlZPW0GQR1XS
DU-4475 MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMESyOFQh|ryP NHPv[W5USU6JRWK=
IST-SL2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnpcGJEUUN3ME2wMlA1Ojd3IN88US=> MXjTRW5ITVJ?
NCI-H82 NEnveHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMESzNFch|ryP NIfWfJVUSU6JRWK=
LC4-1 M2C2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMESzOVEh|ryP NX3WZpZWW0GQR1XS
HDLM-2 M1e0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfPN3J5UUN3ME2wMlA1Ozl{IN88US=> NWS0WIpiW0GQR1XS
MMAC-SF M4HMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H0dmlEPTB;MD6wOFU{PCEQvF2= NILhdZRUSU6JRWK=
L-540 NYnhdHM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zlbWlEPTB;MD6wOFY{QSEQvF2= NUnzVlhmW0GQR1XS
MZ2-MEL M2faOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DoSGlEPTB;MD6wOFc1OiEQvF2= M2LYcnNCVkeHUh?=
LU-134-A NEfjcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMES3O|Mh|ryP NV71N4d5W0GQR1XS
UACC-257 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnpNlBKSzVyPUCuNFQ5PDlizszN NYe5XpNFW0GQR1XS
NCI-H1581 NVvPXolOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHkVm5HUUN3ME2wMlA1QTV|IN88US=> M{\4O3NCVkeHUh?=
NB17 NGPtTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\GTWM2OD1yLkC0PVc6KM7:TR?= MUfTRW5ITVJ?
SBC-1 M{nGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fVcGlEPTB;MD6wOVA1OiEQvF2= M3fvO3NCVkeHUh?=
TALL-1 NX:xUoR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M133SWlEPTB;MD6wOVA1PSEQvF2= M4fkVXNCVkeHUh?=
NCI-H1304 NWHDUI17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWxU2NKSzVyPUCuNFUzODhizszN M3rMU3NCVkeHUh?=
NEC8 MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPxWG1EUUN3ME2wMlA2Ojh4IN88US=> NVO5UWtOW0GQR1XS
CAL-148 NGDlWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMEW0N|kh|ryP NUXHeJFOW0GQR1XS
CGTH-W-1 NGTYRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEW0OFkh|ryP Mle2V2FPT0WU
NCI-H889 NUW3XHJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMEW1PVIh|ryP NXTUd401W0GQR1XS
GR-ST MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nTb2lEPTB;MD6wOVYzOSEQvF2= MmT3V2FPT0WU
KARPAS-422 NVPuc|JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv4WVVjUUN3ME2wMlA2PjVizszN NH:2R4RUSU6JRWK=
RPMI-8866 M1vWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC5TWM2OD1yLkC1O|EzKM7:TR?= MXXTRW5ITVJ?
SCLC-21H Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfITWM2OD1yLkC1PFg1KM7:TR?= M2WwVnNCVkeHUh?=
COR-L88 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPhTWM2OD1yLkC1PVI4KM7:TR?= M3f3cXNCVkeHUh?=
LU-139 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknDTWM2OD1yLkC1PVg3KM7:TR?= NVSwcnFnW0GQR1XS
SF126 M3jFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwME[xN|Mh|ryP Mo\oV2FPT0WU
NCI-H1882 NUPoXJFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzu[5RKSzVyPUCuNFY1OjRizszN MkDvV2FPT0WU
EW-24 M{\mV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nBdWlEPTB;MD6wOlQ5OyEQvF2= Mn\NV2FPT0WU
CP67-MEL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwME[4NUDPxE1? MUXTRW5ITVJ?
DG-75 MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwME[4PVkh|ryP MmLFV2FPT0WU
LOXIMVI MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXWTWM2OD1yLkC3NFI5KM7:TR?= MkfxV2FPT0WU
HH M2THdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHWTJFbUUN3ME2wMlA4OTV5IN88US=> MUfTRW5ITVJ?
K5 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zLeWlEPTB;MD6wO|IzPiEQvF2= MVjTRW5ITVJ?
EC-GI-10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XjUGlEPTB;MD6wO|I2PyEQvF2= Mki3V2FPT0WU
SK-N-DZ NFLpT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMEezNFch|ryP MofHV2FPT0WU
A3-KAW NEPsblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XMO2lEPTB;MD6wO|M2OSEQvF2= NFjGXFJUSU6JRWK=
MLMA M2LVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEe0OlUh|ryP NGHxZVRUSU6JRWK=
LB996-RCC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rxZWlEPTB;MD6wO|cxPyEQvF2= M1PIeHNCVkeHUh?=
OS-RC-2 NUDXVpN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nYdGlEPTB;MD6wO|c1QCEQvF2= MVzTRW5ITVJ?
CTB-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfJNmVKSzVyPUCuNFc5OSEQvF2= NHXVZZdUSU6JRWK=
IST-MES1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz0UYlKSzVyPUCuNFc6OTJizszN Mkj6V2FPT0WU
LS-1034 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHjU4hKSzVyPUCuNFgxOzVizszN NUCwRppmW0GQR1XS
HT MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT3ZWU4UUN3ME2wMlA5ODh4IN88US=> M17wVnNCVkeHUh?=
NCI-H2141 M1fz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjIbINKSzVyPUCuNFgyKM7:TR?= MkLnV2FPT0WU
LB2518-MEL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nKZ2lEPTB;MD6wPFE1OSEQvF2= NHXvcZJUSU6JRWK=
GI-ME-N MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTHTWM2OD1yLkC4OFUzKM7:TR?= M2f5d3NCVkeHUh?=
TGW NX;0WXlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMEi2NFch|ryP NFzTcYRUSU6JRWK=
SK-NEP-1 NUP1cpNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P3WGlEPTB;MD6wPFY1OSEQvF2= NIfVTVhUSU6JRWK=
NOMO-1 M{jPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXqTWM2OD1yLkC5Nlc2KM7:TR?= M3j1Z3NCVkeHUh?=
ES6 NW\6VWFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDKOZV5UUN3ME2wMlA6PTh7IN88US=> NVLYc|FtW0GQR1XS
NCI-H209 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEm3PFYh|ryP MmHXV2FPT0WU
GAK MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\rTWM2OD1yLkGwNVYh|ryP M3y0WHNCVkeHUh?=
BC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G3emlEPTB;MD6xNFM3OSEQvF2= MYfTRW5ITVJ?
KLE MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCxZWc{UUN3ME2wMlExPDR|IN88US=> NGHwbmlUSU6JRWK=
EW-3 M1f6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMUC5PEDPxE1? NHHjU4tUSU6JRWK=
NKM-1 NUnIb4dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPWOZBKSzVyPUCuNVEyKM7:TR?= Mor5V2FPT0WU
D-336MG MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P6TWlEPTB;MD6xNVI1PCEQvF2= NXPaSJlxW0GQR1XS
NB69 M{CyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u1bGlEPTB;MD6xNVMxOSEQvF2= MkDDV2FPT0WU
D-263MG NGfWXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG1TWM2OD1yLkGxO|EzKM7:TR?= MUjTRW5ITVJ?
KP-N-YS M4HDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvVTWM2OD1yLkGyNlkyKM7:TR?= NVzLV3MzW0GQR1XS
NCI-H1155 NFnSPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTOSIFKSzVyPUCuNVI2PThizszN Ml;4V2FPT0WU
BOKU NHnHUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HMPWlEPTB;MD6xNlU4QSEQvF2= NXP5d3dWW0GQR1XS
LAMA-84 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zXUGlEPTB;MD6xNlk6KM7:TR?= MVLTRW5ITVJ?
Raji NG\Kd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnsTWM2OD1yLkGzNVE4KM7:TR?= NEHMXVlUSU6JRWK=
LU-65 NXzaXWRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\nTWM2OD1yLkGzN|A4KM7:TR?= M{XGenNCVkeHUh?=
NCI-H187 NFjU[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[wOoZKSzVyPUCuNVM6OjRizszN MU\TRW5ITVJ?
GCIY NF70fpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrPbHVKSzVyPUCuNVQ6ODFizszN MVfTRW5ITVJ?
NCI-H2107 NH[yW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjSTWM2OD1yLkG1NFgh|ryP MlLPV2FPT0WU
NCI-H1522 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMUWyOlYh|ryP MXHTRW5ITVJ?
NB6 NH;DNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDkfG1KSzVyPUCuNVU3OjNizszN MYHTRW5ITVJ?
EM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7HbploUUN3ME2wMlE2PzB4IN88US=> NY\yRlR4W0GQR1XS
HCC2218 M33LW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2np[mlEPTB;MD6xOVk5KM7:TR?= M4DuRXNCVkeHUh?=
NCI-H748 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jsSmlEPTB;MD6xOlM4PiEQvF2= NYrB[IpCW0GQR1XS
MS-1 MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLETWM2OD1yLkG2OVM4KM7:TR?= MXvTRW5ITVJ?
NB5 NV7tb3ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDvU5k5UUN3ME2wMlE3PTl5IN88US=> NFqxd2JUSU6JRWK=
OMC-1 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMU[2PFgh|ryP NFrKfo1USU6JRWK=
NCI-H345 NWDMelRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2wTWM2OD1yLkG2PVI5KM7:TR?= MWnTRW5ITVJ?
L-428 MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHxTWhKSzVyPUCuNVY6PDVizszN MWTTRW5ITVJ?
SCH MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMUi2PFUh|ryP NEW3bWpUSU6JRWK=
NCI-H1417 M4ntfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMUmyNlch|ryP M{W3XXNCVkeHUh?=
COLO-320-HSR M{fzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMUm1N|Ih|ryP MV7TRW5ITVJ?
BT-474 NYfBemdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe1TWM2OD1yLkKwPFkzKM7:TR?= MXvTRW5ITVJ?
GDM-1 Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\afpZKSzVyPUCuNlE6PzFizszN MojmV2FPT0WU
NCI-H2196 NFvyU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPwd4VKSzVyPUCuNlIzOzVizszN M1S3[XNCVkeHUh?=
KP-N-RT-BM-1 Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLxcZk6UUN3ME2wMlIzOzR7IN88US=> NVL4SndPW0GQR1XS
KNS-81-FD NVvhOHJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7MTWM2OD1yLkKyPVU5KM7:TR?= M2CwfHNCVkeHUh?=
COLO-668 NV3peplwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH6UFlKSzVyPUCuNlM3PzVizszN NHOwXVZUSU6JRWK=
C2BBe1 MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XyXWlEPTB;MD6yOlc1PyEQvF2= NXu0dVA6W0GQR1XS
Ramos-2G6-4C10 NHLBTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HXR2lEPTB;MD6yOlk2PCEQvF2= NEPwOG1USU6JRWK=
CAS-1 NHPNRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M165TWlEPTB;MD6yO|A6PiEQvF2= MYnTRW5ITVJ?
GOTO Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L6Z2lEPTB;MD6yO|g6PCEQvF2= M{[xSHNCVkeHUh?=
LP-1 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;tS2lEPTB;MD6yPFA2PyEQvF2= MnvwV2FPT0WU
NCI-SNU-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMkm0NlIh|ryP NHP0bIZUSU6JRWK=
EB-3 NXmwbI5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMkm5O|kh|ryP NHLUclFUSU6JRWK=
MHH-NB-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC4TWM2OD1yLkOwOFAzKM7:TR?= Mlz6V2FPT0WU
SK-N-FI M37ZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrlUIhKSzVyPUCuN|E3QTJizszN NGL4OFJUSU6JRWK=
HCC2157 NXjofXdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTaTWM2OD1yLkOzPVE{KM7:TR?= NHG2TIFUSU6JRWK=
SIMA NUTWVGNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\ETWM2OD1yLkO0OVgyKM7:TR?= NInQZYZUSU6JRWK=
MDA-MB-134-VI MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrtXW5KSzVyPUCuN|Y6OjhizszN NFj6[WtUSU6JRWK=
NCI-H1694 NVT5bYJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\0OHRKSzVyPUCuN|ch|ryP NHT1XHRUSU6JRWK=
EHEB NESyO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Kz[GlEPTB;MD6zPVA5PSEQvF2= NFrRbIVUSU6JRWK=
U-266 M1nuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXyPYxKSzVyPUCuN|k5PDZizszN Mly0V2FPT0WU
LC-1F M4\YeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVmzZlFHUUN3ME2wMlQ{PzZ3IN88US=> NIj6UoFUSU6JRWK=
SHP-77 Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17EN2lEPTB;MD60O|g2PSEQvF2= M3jlSHNCVkeHUh?=
LS-513 NYLWOYtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGxTWM2OD1yLkS5N|A4KM7:TR?= NHLrbGtUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[4]

+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents individually and in order:
5% DMSO+5% Tween 80+ddH2O
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID